Latest eFlow Technology Stories
DENVER, April 8, 2011 /PRNewswire/ -- A state-of-the-art, eFlow Technology nebulizer (PARI Pharma GmbH) has lifted one Denver Zoo orangutan's health and spirits.
MONTEREY, Calif., Feb.
MONTEREY, Calif., Sept. 23 /PRNewswire/ -- PARI Pharma's Altera, which uses eFlow Technology, is the first drug-specific nebuliser for cystic fibrosis and has been specifically developed to deliver Gilead Sciences' Cayston.
MONTEREY, Calif., Sept. 14 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. reported positive top line results from a Phase 2b clinical trial with Aeroquin, a novel aerosol formulation of levofloxacin delivered by an optimized Investigational eFlow Nebulizer System from PARI Pharma.
MONMOUTH JUNCTION, N.J., Sept. 14 /PRNewswire/ -- Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation).
Positive Results Based on New DSCG Formulation & eFlow Technology Delivery MUNICH and MONTEREY, Calif., May 20 /PRNewswire/ -- This week, Swiss researchers presented positive data from an ongoing Phase II clinical study at the American Thoracic Society (ATS) International Conference that compared PARI Pharma's inhaled IsoCrom, an isotonic 1% disodium cromoglycate (DSCG) solution, to inhaled corticosteroids (ICS) in 28 children with atopic asthma.
- A gift; a largess; a gratuity; a present; a dole.